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Investigating lupus retention in care to
inform interventions for disparities
reduction: an observational cohort study
Christie M. Bartels1,2* , Ann Rosenthal3,4, Xing Wang5,6, Umber Ahmad3, Ian Chang3,7, Nnenna Ezeh8,
Shivani Garg1, Maria Schletzbaum8 and Amy Kind2,9,10
Abstract
Background: Systemic lupus erythematous (SLE) disproportionately impacts patients of color and
socioeconomically disadvantaged patients. Similar disparities in HIV were reduced through a World Health
Organization-endorsed Care Continuum strategy targeting “retention in care,” defined as having at least two annual
visits or viral load lab tests. Using similar definitions, this study aimed to examine predictors of lupus retention in
care, to develop an SLE Care Continuum and inform interventions to reduce disparities. We hypothesized that Black
patients and those residing in disadvantaged neighborhoods would have lower retention in care.
Methods: Abstractors manually validated 545 potential adult cases with SLE codes in 2013–2014 using 1997
American College of Rheumatology (ACR) or 2012 Systemic Lupus Erythematosus International Collaborating Clinics
(SLICC) criteria. We identified 397 SLE patients who met ACR or SLICC criteria for definite lupus, had at least one
baseline rheumatology visit, and were alive through 2015. Retention in care was defined as having two ambulatory
rheumatology visits or SLE labs (e.g., complement tests) during the outcome year 2015, analogous to HIV retention
definitions. Explanatory variables included age, sex, race, ethnicity, smoking status, neighborhood area deprivation
index (ADI), number of SLE criteria, and nephritis. We used multivariable logistic regression to test our hypothesis
and model predictors of SLE retention in care.
Results: Among 397 SLE patients, 91% were female, 56% White, 39% Black, and 5% Hispanic. Notably, 51% of Black
versus 5% of White SLE patients resided in the most disadvantaged ADI neighborhood quartile. Overall, 60% met
visit-defined retention and 27% met complement lab-defined retention in 2015. Retention was 59% lower for
patients in the most disadvantaged neighborhood quartile (adjusted OR 0.41, CI 0.18, 0.93). No statistical difference
was seen based on age, sex, race, or ethnicity. More SLE criteria and non-smoking predicted greater retention.
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© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: cb4@medicine.wisc.edu
This research was presented in a podium presentation at the American
College of Rheumatology Annual Meeting, October 21, 2018, Chicago IL.
Defining and Examining Retention in Care in an Urban Lupus Cohort
[abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). Findings have not been
published previously beyond abstract form.
1Department of Medicine, Rheumatology Division, University of Wisconsin
School of Medicine and Public Health, 1485 Highland Ave, Rm 4132,
Madison, WI 53705, USA
2Health Services & Care Research Program, Department of Medicine,
University of Wisconsin School of Medicine and Public Health, Madison, WI,
USA
Full list of author information is available at the end of the article
Bartels et al. Arthritis Research & Therapy           (2020) 22:35 
https://doi.org/10.1186/s13075-020-2123-4
(Continued from previous page)
Conclusions: Disadvantaged neighborhood residence was the strongest factor predicting poor SLE retention in
care. Future interventions could geo-target disadvantaged neighborhoods and design retention programs with
vulnerable populations to improve retention in care and reduce SLE outcome disparities.
Keywords: Systemic lupus erythematosus, Health disparities, Social determinants of health, Retention in care, Health
care quality
Background
Systemic lupus erythematosus (SLE) is an auto-
immune disease that disproportionately impacts young
women, patients of color, and the socioeconomically
disadvantaged, making SLE an important target for
health disparity measurement and research [1]. Des-
pite many effective lupus monitoring strategies and
treatments [2, 3], significant healthcare disparities and
outcome gaps remain [4–6]. Compared to White
women, the US Black women are up to seven times
more likely to develop renal failure, and two to three
times as likely to die prematurely [4, 7]. SLE is also a
leading chronic disease cause of death in the US
women ages 18–25 [8]. Arguing against a purely bio-
logical mechanism, higher SLE damage was noted in
the US African descendants but not in other African
descendants in ten other countries in the SLICC co-
hort [9]. High-quality clinical care can reduce risk for
many poor lupus outcomes [10, 11]. Yet, some data
suggest that Black or low SES patients with milder
onset SLE are more likely to ultimately die of their
disease, suggesting that differences in healthcare
follow-up might be to blame [7, 12].
Human immunodeficiency virus (HIV), which also dis-
proportionately impacts young, Black, and socioeconom-
ically disadvantaged populations, is an analogous
condition where healthcare gaps have been targeted as a
means by which to reduce disparities. As a framework,
experts at the World Health Organization (WHO) [13],
US Institute of Medicine (IOM) [14], and Centers for
Disease Control and Prevention (CDC) [15] have defined
an “HIV Care Continuum” outlining five critical health-
care steps to achieve successful viral suppression. The
Care Continuum offers standard definitions to measure
gaps at each step from (1) diagnosis to (2) linkage with
specialty HIV care, (3) retention in care, and (4) reten-
tion on antiretroviral therapy, and finally to (5) control
with suppressed HIV viral loads [16]. Using this con-
tinuum, HIV researchers determined that gaps in reten-
tion in care account for most (61%) failures to control
HIV [16]. Moreover, continuum research has led to a
compendium of evidence-based interventions [15] to
close gaps at each step including many interventions to
improve retention in HIV care. A similar approach holds
promise for improving disparities in SLE. As such, we
proposed an SLE Care Continuum from (1) diagnosis to
(2) linkage with specialty lupus care, (3) retention in
care, (4) retention on immune therapy, and finally (5)
low lupus disease activity (Fig. 1). In this study, we first
focus on predictors of retention in care.
Rheumatologists often observe that keeping some
lupus patients, particularly young, Black, or socioeco-
nomically disadvantaged lupus patients [17], in follow-
up care is a challenge, yet no metrics exist to identify
who is or is not retained in lupus care. In HIV, retention
in care is defined by WHO [13] and CDC [15] experts as
having two annual HIV visits or one viral load every
6 months. Creating such metrics was pivotal for identify-
ing gaps and testing strategies to reduce HIV health dis-
parities [15]. Despite an urgent need to reduce SLE
disparities and known concerns regarding retention, we
have no established methods to measure gaps in reten-
tion in care or other disparities across an SLE Care
Continuum.
We were particularly interested in investigating rela-
tionships between race, socioeconomic disadvantage,
and retention in lupus care in this cohort [18]. Black pa-
tients and the socioeconomically disadvantaged are more
likely to reside in disadvantaged US neighborhoods,
which are linked to high disease rates and mortality of-
fering geographic targets for policy, practice change, and
research [19, 20].
We hypothesized that Black patients and those resid-
ing in highly disadvantaged neighborhoods would have
lower retention in care because of the multitude of so-
cioeconomic, access, and other adverse social determi-
nants of health that such residents face [21–23]. The
objectives of this study were to validate an urban lupus
cohort, to create metrics for retention in care, and to
examine how race and other social determinants of
health predict lupus retention in care. Defining lupus re-
tention in care and its predictors are key steps toward
designing future interventions to improve retention and
reduce lupus outcome disparities.
Methods
Inclusion and study population
For this cohort study, we first searched all Jan 2013–
June 2014 electronic health records (EHR) at an urban
US academic center for all inpatient or outpatient visits
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with the International Classification of Diseases ninth or
tenth edition (ICD-9 or 10) codes representing possible
SLE [ICD-9 710.0 or ICD-10 M32, M32.1, M32.8,
M32.9]. Inclusion required being age 18 or over, living
through 2015 to assure eligibility for retention in care,
and having at least one ambulatory visit in rheumatology
[physician (MD, DO), nurse practitioner (NP), physician
assistant (PA), resident, or fellow] and one in primary
care (family medicine, internal medicine, geriatrics, ob-
stetrics and gynecology, or pediatrics) in 2013–2014 to
assure equal capture of baseline comorbidity and health-
care utilization information and follow-up. Recognizing
that not all patients with lupus diagnosis codes meet
clinical criteria, trained health professionals manually
validated all potential SLE cases using a standard RED-
Cap abstraction tool to assess the 1997-modified 1982
American College of Rheumatology (ACR) classification
criteria and 2012 Systemic Lupus Collaborating Clinics
(SLICC) SLE classification criteria [24]. Laboratory,
pathology, imaging, and clinical note data were reviewed
for all patients with possible lupus. Those with drug-
induced lupus or not meeting either definite classifica-
tion of SLE were excluded. All patients meeting either
the 1997 ACR or 2012 SLICC SLE classification criteria
and other inclusion criteria were included in the study.
Patients were followed from the study start date of their
first lupus diagnosis code, through death, or the end of
2015 as a study end date. Data elements for each indi-
vidual were linked via a unique pseudo identifier, and
direct identifiers were removed for a final limited dataset
for analysis.
The Institutional Review Board approved of this min-
imal risk medical record review study with a waiver of
individual informed consent and use of a limited dataset.
Data sources
In addition to manually abstracted items, EHR data were
electronically extracted for definite SLE cases including
(1) patient-level sociodemographic variables (age, sex,
race, ethnicity, rural-urban commuting area (RUCA)
classification, date of death), (2) visit-level information
(all rheumatology encounter dates and all encounter
ICD codes), and (3) select laboratory data (e.g., C3/C4
complement and anti-double-stranded DNA antibody
testing dates). In addition to SLE classification criteria,
sociodemographic and behavioral factors also reviewed
during manual abstraction were nine-digit ZIP postal
code and smoking history. Disease severity was noted
using the number of SLE criteria, and a history of lupus
nephritis was also manually validated.
Outcome definitions for lupus retention in care
EHR dates of rheumatology visits attended and complete
blood count (CBC), creatinine anti-double-stranded
DNA (dsDNA), or C3 or C4 complement tests during
the calendar year 2015 were used to test potential reten-
tion definitions. Thresholds of one, two, or four visits or
complement or dsDNA lab tests were compared. We fo-
cused on two visit-defined and two lab-defined SLE re-
tention in care in those without nephritis analogous to
HIV definitions and consistent with guidelines for neph-
ritis screening and quality measures [2, 11]. We also
tested a four lab-defined threshold consistent with SLE
guidelines for those with lupus nephritis [2, 3]. Non-
specific tests such as complete blood counts and creatin-
ine were tested but not used as final definitions as they
may be ordered by other providers for other non-SLE
reasons and may not indicate lupus retention in care.
Tests such as urinalyses, while important to most lupus
care, were avoided given that SLE patients on dialysis
may forgo such testing or have results at external dialysis
centers and thus not present in EHR data.
Predictors and covariates
Consistent with the National Institute of Minority
Health and Health Disparities research framework [21],
multilevel predictors of interest included individual-level
age, sex, race, ethnicity, and smoking status, and ZIP
code linked contextual-level rural urban (RUCA) classifi-
cation, and neighborhood disadvantage quartile. We
used the Area Deprivation Index (ADI), a neighborhood
disadvantage metric encompassing 17 education, em-
ployment, housing quality, transportation, and poverty
measures to match from 69 million nine-digit ZIP postal
Fig. 1 Proposed SLE Care Continuum adapted with permission from the HIV.gov Care Continuum
Bartels et al. Arthritis Research & Therapy           (2020) 22:35 Page 3 of 9
code census block groups, i.e., “neighborhoods” of ap-
proximately 1500 people [19, 20, 25]. Twenty-five pa-
tients were missing residential ADI data and were
excluded from multivariable modeling. The number of
ACR criteria and any history of nephritis were included
as markers of lupus severity.
Statistical analysis
Baseline lupus cohort characteristics were presented as
frequencies and proportions for the overall and the cohort
stratified by race. Differences between proportions were
examined by the chi-square test. Retention rates during
the 2015 period were calculated as percent of eligible pa-
tients meeting visit or laboratory testing definitions. We
also examined definitions specific to guideline-
recommended lab frequencies for those with lupus neph-
ritis [2, 12]. Next, to determine predictors of retention,
univariate and multivariable logistic regression analyses
were performed, and results are presented as odds ratios
(ORs) along with 95% confidence intervals (CIs). Potential
interactions between ADI neighborhood disadvantage and
other covariates (e.g., race or ethnicity) were tested as sen-
sitivity analyses. We a priori estimated 80% power to de-
tect an odds ratio of 0.60 if retention in care is 65% in
White compared to 53% in Black patients using a two-
sided Z test, significance level 0.05, similar to a 15% re-
ported race gap in medication adherence [26]. Analyses
were completed using SAS version 9.4 (Cary, NC) and
STATA version 13.1 (College Station, TX).
Results
Cohort description
Of 528 abstracted potential lupus cases, 397 patients
met ACR or SLICC classification criteria for definite
lupus and were included in our study (Fig. 2). Among
definite lupus patients, 91% were female, 39% Black, 5%
Other, and 4% Hispanic (see Table 1).
Compared to White patients with lupus, Black patients
were younger, more likely to reside in urban areas, and
10 times more likely to reside in a neighborhood within
the most disadvantaged quartile (51% Blacks vs. 5%
Whites). Black patients were also more likely to meet
ACR SLE criteria (95% vs. 87%). Payer varied signifi-
cantly by race (75% of Black versus 40% of White pa-
tients received public insurance), and only 2% of patients
were uninsured or had unknown payer status.
Testing retention definitions
When examining definitions of lupus retention in care,
we first examined visit-based definitions similar to those
employed in HIV. Overall, as shown in Table 2, 83%
(n = 331) of eligible lupus patients had at least one am-
bulatory rheumatology visit in 2015, and 60% (n = 238)
had at least two visits. This was comparable to 74% with
two or more visits in the baseline year 2014 (data not
shown).
When testing lab-defined retention in care, we se-
quentially examined C3 and C4 complement, CBC,
creatinine, and anti-dsDNA testing (Table 2). In 2015
follow-up, 54% of patients had at least one CBC and
46% of patients had at least one complement result
recorded in the EHR. Only 27% and 41% had two an-
nual complement and creatinine tests, respectively,
compared to 43% with at least two complement tests
in the 2014 baseline year (data not shown). Any sin-
gle anti-dsDNA result was available on only 29% of
the cohort during 2015, with only 19% having two
dsDNA tests, leading us to operationalize the equally
specific two complement test definition for lab-
defined lupus retention in care for multivariable mod-
eling although other definitions could be assessed in
future studies.
Predictors of lupus retention in care
In adjusted multivariable models, residing in the neigh-
borhood quartile with worst disadvantage was the stron-
gest predictor of lower retention in care, predicting
nearly 60% lower odds (OR 0.41, CI 0.18, 0.93; Table 3).
Smoking likewise significantly predicted lower visit-
defined retention in care (OR 0.63, 0.40, 0.99). Neither
Black race nor Hispanic ethnicity was predictive of lupus
retention in care.
Examining unadjusted odds using the two comple-
ment definitions of retention, nephritis predicted
greater retention (OR 1.70, CI 1.12, 2.59; Table 4);
small town residence predicted lower lab-defined
Fig. 2 Flow diagram of project design and inclusion
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retention. However, in multivariate models, nephritis
patients did not have significantly different retention
(OR 1.41, CI 0.82, 2.41) and only a higher number of
SLE criteria predicted greater retention (OR 1.17, CI
1.01, 1.35).
Among 145 patients with lupus nephritis, slightly more
(66 vs. 60%) met the two visit-defined retention criteria.
Likewise, 34% vs. 27% had at least two complement
tests, but in such patients, only 14% had four tests per
year as recommended per ACR guidelines for lupus
nephritis [2].
Discussion
Using definitions analogous to those used by the
WHO, IOM, and CDC [13–15] to define HIV reten-
tion in care, we were able to define and examine pre-
dictors of lupus retention in care. We examined both
visit and lab-defined retention in care noting that
40% of patients lacked recommended visits and more
than half of patients lacked recommended lupus labs.
Notably, our visit-based models revealed that neigh-
borhood disadvantage was the strongest predictor of
gaps in lupus retention in care. Patients with lupus
nephritis performed slightly better using basic mea-
sures, but only 14% met guideline recommended
quarterly lab-defined retention.
More broadly, our data, and those of others [27, 28],
support defining and investigating a Care Continuum
across lupus care to inform the design of targeted inter-
ventions to eliminate disparities. Supporting the idea
that the SLE Care Continuum would likewise correlate
with outcomes, prior studies have shown retention on
Table 1 Prevalent systemic lupus erythematosus cohort
description (n = 397)
Total cohort White/other Black p
n = 397 n = 241 n = 156
Age category
18–29 54 (13.6%) 30 (12.5%) 24 (15.4%) < 0.001
30–40 96 (24.2%) 50 (20.8%) 46 (29.5%)
40–60 175 (44.1%) 102 (42.3%) 73 (46.8%)
60–80 67 (16.9%) 56 (23.2%) 11 (7.1%)
80+ 5 (1.3%) 3 (1.2%) 2 (1.3%)
Female 361 (90.9%) 219 (90.9%) 142 (91.0%) 0.96
Race
White 221 (55.7%) 221 (91.7%) NA < 0.001
Black 156 (39.3%) NA 156 (100%)
Other 20 (5.0%) 20 (8.3%) NA
Ethnicity
Hispanic 17 (4.3%) 16 (6.6%) 2 (1.3%) 0.01
RUCA
Urban 329 (82.9%) 175 (72.6%) 154 (98.7%) < 0.001
Suburban 36 (9.1%) 36 (14.9%) 0 (0%)
Large town 15 (3.8%) 14 (5.8%) 1 (0.6%)
Small town 17 (4.3%) 16 (6.6%) 1 (0.6%)
Smoking (ever) 168 (42.3%) 103 (43%) 65 (42%) 0.60
Payer
Commercial 176 (44.3%) 139 (57.7%) 37 (23.7%) < 0.001
Medicaid 71 (17.9%) 24 (10.0%) 47 (30.1%)
Medicare 142 (35.8%) 72 (29.9%) 70 (44.9%)
Uninsured/
unknown
8 (2.0%) 6 (2.5%) 2 (0.06%)
Neighborhood disadvantage by ADI quartile
1st (least
disadvantage)
93 (25.0%) 83 (34.4%) 10 (6.4%) < 0.001
2nd 93 (25.0%) 78 (32.4%) 15 (9.6%)
3rd 93 (25.0%) 54 (22.4%) 39 (25.0%)
4th (most
disadvantage)
93 (25.0%) 13 (5.4%) 80 (51.3%)
Positive ACR criteria 365 (91.9%) 210 (87.1%) 148 (94.9%) 0.02
Table 2 Examining visit- and lab-defined retention in care
thresholds in SLE cases with and without nephritis (n = 397)
All SLE Lupus nephritis p
n = 397 n = 145
Definition Interval n % n %
Visit definitions
Rh visits ≥ 1/year 331 83 120 83 0.802
*Rh visits ≥ 2/year 238 60 96 66 0.054
Rh visits ≥ 4/year 79 20 46 32 < 0.001
Lab definitions
C3/C4 ≥ 1/year 184 46 78 54 0.024
*C3/C4 ≥ 2/year 106 27 49 34 0.015
C3/C4 ≥ 4/year 30 8 20 14 < 0.001
CBC ≥ 1/year 213 54 90 62 0.011
CBC ≥ 2/year 159 40 72 50 0.001
CBC ≥ 4/year 93 23 52 36 0.003
Creatinine ≥ 1/year 211 53 89 61 0.013
Creatinine ≥ 2/year 163 41 74 51 0.002
Creatinine ≥ 4/year 92 23 49 34 < 0.001
dsDNA ≥ 1/year 149 38 67 46 0.007
dsDNA ≥ 2/year 77 19 39 27 0.004
dsDNA ≥ 4/year 18 5 12 8 0.007
Abbreviations: Rh rheumatology MD, DO, NP, PA, or fellow; C3/C4 complement
component 3 or 4 lab tests which were each independently assessed yielding
identical results that are shown together; CBC complete blood counts; dsDNA
double-stranded DNA antibody test
*Final models used two visits and at least two labs per year consistent with
WHO/CDC HIV definitions and ACR SLE guidelines
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therapy for instance links to patient outcomes in SLE.
Specifically, hydroxychloroquine improves outcomes [6],
and nonadherence gaps correlate with worse outcomes,
particularly, in disparities populations [27, 28]. A Canad-
ian study correlated better hydroxychloroquine adher-
ence with 5-year reductions in cumulative steroid use,
disease activity, and lupus damage [28]. Conversely, a US
Medicaid study reported that hydroxychloroquine ther-
apy gaps (as defined by < 80% medication possession)
were seen in 83% of patients and correlated with in-
creased emergency visits and hospitalizations by
4 months [27]. We focused upstream in the Care Con-
tinuum noting that retention in care is critical to receive
prescriptions for such treatments, to decrease treatment
interruptions, and to signal treatment escalation when
necessary.
Based on prior literature describing outcome dispar-
ities and follow-up gaps in Black patients or those from
socioeconomic disadvantaged backgrounds [17], we pre-
dicted lower retention in care in those groups. We ob-
served that neighborhood disadvantage was most
strongly predictive, independent of race. Geographically,
our site for this study, urban Milwaukee, WI, USA, may
be more segregated than other cities [29] influencing the
relative weights of predictors. We observed that 51% of
Black patients with SLE resided in the most disadvan-
taged quartile neighborhoods compared to only 5% of
White patients. Both race and neighborhood
Table 3 Predictors of two visit-defined lupus retention in care
(n = 372, multivariable analysis included 372 of 397 SLE patients
with complete data)
Unadjusted OR
(95% CI)
Adjusted OR
(95% Cl)
Age
18–29 Ref Ref
30–40 0.95 (0.47, 1.93) 0.81 (0.36, 1.81)
40–60 0.65 (0.34, 1.24) 0.65 (0.31, 1.36)
60–80 0.62 (0.29, 1.30) 0.71 (0.30, 1.68)
80+ 0.75 (0.11, 4.90) 1.15 (0.11, 12.38)
Female 0.73 (0.35, 1.50) 0.50 (0.22, 1.12)
Race
White Ref Ref
Black 1.24 (0.81, 1.89) 1.56 (0.81, 3.03)
Other 0.71 (0.29, 1.78) 0.98 (0.29, 3.33)
Ethnicity (Hispanic) 0.52 (0.20, 1.34) 0.63 (0.18, 2.28)
RUCA
Urban Ref Ref
Suburban 1.03 (0.51, 2.08) 1.19 (0.54, 2.65)
Large town 1.31 (0.44, 3.91) 1.12 (0.33, 3.88)
Small town 0.46 (0.17, 1.23) 0.41 (0.14, 1.23)
Ever Smoking 0.63 (0.42, 0.95) 0.63 (0.40, 0.99)
Payer
Commercial Ref
Medicaid 0.72 (0.41, 1.25)
Medicare 1.25 (0.79, 1.98)
Neighborhood disadvantage by ADI
1st (least disadvantage) Ref Ref
2nd quartile 1.05 (0.58, 1.88) 1.02 (0.55 (1.92)
3rd quartile 1.26 (0.69, 2.29) 1.01 (0.52, 2.00)
4th (most disadvantage) 0.74 (0.41, 1.32) 0.41 (0.18, 0.93)
Number of ACR criteria 1.13 (1.01, 1.27) 1.10 (0.95, 1.27)
Lupus nephritis 1.52 (0.99, 2.32) 1.35 (0.78, 2.36)
Table 4 Predictors of two complement lab-defined retention in
care (n = 372, multivariable analysis included 372 of 397 SLE
patients with complete data)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Age
18–29 Ref Ref
30–40 0.93 (0.47, 1.86) 1.10 (0.51, 2.39)
40–60 1.28 (0.68, 2.39) 1.68 (0.83, 3.41)
60–80 0.89 (0.42, 1.88) 1.40 (0.59, 3.30)
80+ 1.13 (0.17, 7.37) 2.94 (0.36, 24.28)
Female 0.77 (0.39, 1.54) 0.77 (0.36, 1.64)
Race
White Ref Ref
Black 1.29 (0.85, 1.97) 0.82 (0.43, 1.55)
Other 1.18 (0.46, 3.00) 1.15 (0.34, 3.92)
Ethnicity (Hispanic) 1.00 (0.38, 2.65) 0.99 (0.28, 3.61)
RUCA
Urban Ref Ref
Suburban 0.90 (0.44, 1.84) 1.32 (0.59, 2.95)
Large town 1.82 (0.64, 5.13) 1.63 (0.49, 5.43)
Small town 0.87 (0.50, 0.78) 0.95 (0.32, 2.86)
Ever Smoking 1.08 (0.72, 1.63) 1.01 (0.64, 1.59)
Payer
Commercial Ref
Medicaid 0.92 (0.52, 1.62)
Medicare 1.13 (0.72, 1.77)
Neighborhood disadvantage by ADI
1st (least disadvantage) Ref Ref
2nd quartile 0.87 (0.47, 1.59) 0.80 (0.42, 1.51)
3rd quartile 1.20 (0.66, 2.18) 1.10 (0.56, 2.15)
4th (most disadvantage) 1.56 (0.88, 2.82) 1.39 (0.94, 3.04)
Number of ACR criteria 1.19 (1.06, 1.33) 1.17 (1.01, 1.35)
Lupus nephritis 1.70 (1.12, 2.59) 1.41 (0.82, 2.41)
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disadvantage in addition to other factors may be predict-
ive of retention in care in other places, yet data suggest
that neighborhood disadvantage predicts health inde-
pendent of individual socioeconomic status as well [30].
Neighborhood context can directly affect access to
healthcare as well as access to transportation, food, edu-
cation, health behaviors, safety, discrimination, and
chronic stress influencing many health outcomes [22, 23,
31]. Mechanistically, if transportation is less available or
healthcare facilities are farther from disadvantaged pop-
ulations, as shown in a US SLE Medicaid study [32],
then getting routine visits and lab tests is more challen-
ging. A strength of neighborhood disadvantage as a dis-
parities predictor is that it can be calculated using
already collected addresses within EHRs to identify pa-
tients who may need additional resources. It can also be
used as a first step toward additional targeted research
to disentangle the myriad of mechanisms that may
underlie lupus disparities and to specifically target these
actionable factors for interventions across policy, re-
search, and clinical domains.
Retention in care is a well-developed metric in the
HIV literature that has been central to the WHO and
US National HIV/AIDS Strategy [15] and for measur-
ing progress in reducing disparities [33]. Among those
retained in care, 89% received treatment and 80%
achieved viral suppression control, highlighting that
retention in care is a key target. Encouragingly, a
meta-analysis [34] and the compendium [15] highlight
numerous evidence-based interventions proven to im-
prove retention in HIV care and reduce disparities.
Policy-driven programs have used such HIV Care
Continuum strategies to increase viral suppression
from 69 to 81% among Black participants between
2012 and 2016 [35]. Individual patients with HIV now
also know that two viral load lab tests per year define
a minimum standard to share accountability. Overall,
success reducing disparities in HIV highlights the
need to measure SLE retention in care as a necessary
first step toward designing interventions, policies, and
building patient partnerships to eliminate lupus out-
come disparities.
Despite strengths of carefully validating lupus cases,
applying a novel Care Continuum from HIV, and testing
associations using multivariable regression, we also ac-
knowledge limitations. First, our analysis included only
one health system in one US city. Future projects will
test retention definitions in other health systems or re-
gions. Second, patients with nephritis or skin predomin-
ant SLE may be followed more closely in nephrology or
dermatology which was not examined in this study. Fu-
ture studies could examine retention in care including
visits provided by nephrologists or dermatologists, who
may share care for patients with SLE. A strength of our
EHR-derived visit-based approach to define retention is
the possibility of reproducing this metric across or be-
tween health systems. It is possible that compared to
single-system EHR assessments, payer claims datasets
might show higher retention in care given capture of
visit or lab claims anywhere, including labs performed in
other local health systems. For instance, we noted that
small town residents had lower univariate odds of com-
plement tests; some may have had lab testing in local
clinics while others simply did not have tests. Likewise,
only 2% of our cohort was uninsured and retention rates
may vary in populations with more patients who are un-
insured. We also acknowledge that some patients may
have been lost to follow-up—migrating or intentionally
changing insurance or providers, without true gaps in
lupus retention in care. Residence may also change more
frequently in patients with greatest disadvantage or ad-
verse life experiences [36, 37]. Such time-varying factors
could be examined in future multi-site studies.
Conclusions
Defining lupus retention in care and its predictors are
key steps toward future evidence-based interventions to
improve retention and reduce some disparities in lupus
outcomes. Residence in a disadvantaged neighborhood
was the strongest factor predicting poor SLE retention
in care. Constructing future interventions could leverage
geo-targeting disadvantaged neighborhoods, as well as
designing programs specifically with and for vulnerable
populations residing within these neighborhoods. Ultim-
ately, we aim to use the SLE Care Continuum measures
to design evidence-based care strategies and policies to
reduce health disparities and advance outcome equity
among patients with lupus.
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